CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $4,425,400 | -54.5% | 507,500 | -67.3% | 0.87% | -54.4% |
Q4 2022 | $9,718,500 | +247.3% | 1,550,000 | +93.9% | 1.90% | +182.6% |
Q3 2022 | $2,798,000 | -78.9% | 799,439 | -20.0% | 0.67% | -48.7% |
Q1 2019 | $13,265,000 | +18.8% | 998,841 | -29.6% | 1.31% | -6.9% |
Q4 2018 | $11,164,000 | – | 1,418,489 | – | 1.41% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 2,254,502 | $20,741,000 | 14.54% |
Versant Venture Management, LLC | 1,048,601 | $9,647,127,000 | 10.15% |
Abingworth LLP | 1,147,077 | $10,553,000 | 7.65% |
Omega Fund Management, LLC | 551,477 | $5,074,000 | 3.67% |
Opaleye Management Inc. | 665,000 | $6,118,000 | 1.96% |
DAFNA Capital Management LLC | 361,164 | $3,323,000 | 1.79% |
Boxer Capital, LLC | 1,012,986 | $9,319,000 | 1.70% |
Foresite Capital Management III, LLC | 600,000 | $5,520,000 | 1.55% |
NEXTHERA CAPITAL LP | 536,568 | $4,936,000 | 0.91% |
Perceptive Advisors | 2,685,882 | $24,710,000 | 0.82% |